Stock 4595 MIZUHO MEDY CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Mizuho Medy Co.,Ltd.

Equities

4595

JP3885900005

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-05-02 am EDT 		5-day change 1st Jan Change
3,360 JPY +0.15% Intraday chart for Mizuho Medy Co.,Ltd. +1.66% +7.01%
2021 Mizuho Medy Co.,Ltd.(TSE:4595) added to S&P Global BMI Index CI
2020 Mizuho Medy Co.,Ltd.(TSE:4595) dropped from S&P Global BMI Index CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • This company will be of major interest to investors in search of a high dividend stock.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
MIZUHO MEDY CO.,LTD. Stock Mizuho Medy Co.,Ltd.
+7.01% 203M -
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-9.59% 7.67B
B-
DIASORIN S.P.A. Stock DiaSorin S.p.A.
+1.84% 5.41B
B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+8.69% 4.62B
C
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
+0.02% 4.57B
C
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-51.89% 3.22B
D+
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+6.42% 2.59B - -
VITROLIFE AB Stock Vitrolife AB
-13.71% 2.05B
B-
GUANGZHOU WONDFO BIOTECH CO.,LTD Stock Guangzhou Wondfo Biotech Co.,Ltd
-8.29% 1.79B
D+
MYRIAD GENETICS, INC. Stock Myriad Genetics, Inc.
+1.67% 1.76B
C
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4595 Stock
  4. Ratings Mizuho Medy Co.,Ltd.